Literature DB >> 3047411

Update in cancer chemotherapy: genitourinary tract cancer, Part 5: Ovarian cancer.

J C Wright.   

Abstract

An update of the state of the art of cancer chemotherapeutic treatment of genitourinary tract cancer is described in this multi-part series: included are cancers of the kidney, bladder, prostate, testicle, ovary, uterus, vulva, and gestational trophoblastic neoplasms. Part 5 is a review of treatments for cancer of the ovary.Ovarian cancer is the leading cause of gynecologic cancer deaths and the fourth most frequent cause of death from cancer in women in the United States. Ovarian carcinoma is a classical "hidden" neoplasm of the abdomen and, as such, is insidious in its onset. Combination chemotherapy and cytoreductive surgery, however, have provided improved survival for patients with ovarian cancer. As dosage schedules and other refinements are made, the overall outlook for patients with ovarian cancer is promising.

Entities:  

Mesh:

Year:  1988        PMID: 3047411      PMCID: PMC2625767     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  40 in total

1.  A clinical study on the use of chlorambucil in the treatment of cancer of the ovary.

Authors:  J G MASTERSON; R J CALAME; J NELSON
Journal:  Am J Obstet Gynecol       Date:  1960-05       Impact factor: 8.661

2.  Triethylene melamine in the treatment of neoplastic disease.

Authors:  R W RUNDLES; W B BARTON
Journal:  Blood       Date:  1952-05       Impact factor: 22.113

3.  Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.

Authors:  C E Ehrlich; L Einhorn; S D Williams; J Morgan
Journal:  Cancer Treat Rep       Date:  1979-02

4.  Chemotherapy in the treatment of cancer of the ovary.

Authors:  J P Smith; F Rutledge
Journal:  Am J Obstet Gynecol       Date:  1970-07-01       Impact factor: 8.661

5.  Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease.

Authors:  J H Edmonson; T R Fleming; D G Decker; G D Malkasian; E O Jorgensen; J A Jefferies; M J Webb; L K Kvols
Journal:  Cancer Treat Rep       Date:  1979-02

Review 6.  Cyclophosphamide in the treatment of ovarian cancer.

Authors:  D G Decker; E Mussey; G D Malkasian; C E Johnson
Journal:  Clin Obstet Gynecol       Date:  1968-06       Impact factor: 2.190

7.  The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).

Authors:  S E Vogl; M Berenzweig; B H Kaplan; M Moukhtar; W Bulkin
Journal:  Cancer Treat Rep       Date:  1979-02

8.  Hexamethylmelamine. An evaluation of its role in the therapy of cancer.

Authors:  S S Legha; M Slavik; S K Carter
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

9.  Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  W T Creasman; S A Gall; J A Blessing; H J Schmidt; S Abu-Ghazaleh; J K Whisnant; P J DiSaia
Journal:  Cancer Treat Rep       Date:  1979-02

10.  Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma.

Authors:  L M Parker; C T Griffiths; R A Yankee; G P Canellos; R Gelman; R C Knapp; C M Richman; J S Tobias; R S Weiner; E Frei
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.